VPT — VentriPoint Diagnostics Share Price
- CA$36.15m
- CA$34.28m
- CA$0.07m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 27.51 | ||
Price to Tang. Book | 27.51 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1,007.3 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -294.62% | ||
Return on Equity | -141.63% | ||
Operating Margin | -13380.83% |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | 0.06 | 0.08 | 0.04 | n/a | 0.07 | n/a | n/a | 6.19% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).
Directors
- George Adams CHM (70)
- Victor Hugo CFO
- Alvira Macanovic VOP
- Robert Hodgkinson IND
- Hugh MacNaught IND
- Peter Weichler IND
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 18th, 2007
- Public Since
- November 9th, 2005
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 157,182,655
- Address
- 18 Hook Ave, Unit 101, TORONTO, M6P 1T4
- Web
- https://www.ventripoint.com
- Phone
- +1 4168484156
- Contact
- Jonathan Robinson
- Auditors
- MNP LLP
Upcoming Events for VPT
Q1 2024 VentriPoint Diagnostics Ltd Earnings Release
Q2 2024 VentriPoint Diagnostics Ltd Earnings Release
Similar to VPT
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Cloud DX
TSX Venture Exchange
Enablence Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
FAQ
As of Today at 18:23 UTC, shares in VentriPoint Diagnostics are trading at CA$0.23. This share price information is delayed by 15 minutes.
Shares in VentriPoint Diagnostics last closed at CA$0.23 and the price had moved by +9.52% over the past 365 days. In terms of relative price strength the VentriPoint Diagnostics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -2.84% over the past year.
There is no consensus recommendation for this security.
VentriPoint Diagnostics does not currently pay a dividend.
VentriPoint Diagnostics does not currently pay a dividend.
VentriPoint Diagnostics does not currently pay a dividend.
To buy shares in VentriPoint Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.23, shares in VentriPoint Diagnostics had a market capitalisation of CA$36.15m.
Here are the trading details for VentriPoint Diagnostics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: VPT
Based on an overall assessment of its quality, value and momentum VentriPoint Diagnostics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VentriPoint Diagnostics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +1.05%.
As of the last closing price of CA$0.23, shares in VentriPoint Diagnostics were trading -0.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The VentriPoint Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
VentriPoint Diagnostics' management team is headed by:
- George Adams - CHM
- Victor Hugo - CFO
- Alvira Macanovic - VOP
- Robert Hodgkinson - IND
- Hugh MacNaught - IND
- Peter Weichler - IND